Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases

Heart

Volumn 102, Issue 5, 2016, Pages 383-389

  Pujades Rodriguez, Mar ^a,b   Duyx, Bram ^a   Thomas, Sara L ^c   Stogiannis, Dimitris ^a   Smeeth, Liam ^a,c   Hemingway, Harry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; STABLE ANGINA PECTORIS; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; ELECTRONIC HEALTH RECORD; ENGLAND; FACTUAL DATABASE; INFORMATION RETRIEVAL; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; POLYMYALGIA RHEUMATICA; PRIMARY HEALTH CARE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; ENGLAND; FEMALE; GIANT CELL ARTERITIS; HUMANS; INFORMATION STORAGE AND RETRIEVAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; PRIMARY HEALTH CARE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84956707866     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308514     Document Type: Article

References (25)

1. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013;381:63-72.
2. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
3. De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol 2015;42:119-25.
4. Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford) 2012;51:77-86.
5. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8.
6. Uddhammar A, Eriksson AL, Nystrom L, et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42.
7. Hancock AT, Mallen CD, Belcher J, et al. Association between polymyalgia rheumatica and vascular disease: a systematic review. Arthritis Care Res (Hoboken) 2012;64:1301-5.
8. Hancock AT, Mallen CD, Muller S, et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ 2014;186:E495-501.
9. Ungprasert P, Koster MJ, Warrington KJ. Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2015;44:586-91.
10. Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160:73-80.
11. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61.
12. Denaxas SC, George J, Herrett E, et al. Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). Int J Epidemiol 2012;41:1625-38.
13. Pujades-Rodriguez M, George J, Shah AD, et al. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol 2015;44:129-41.
14. Pujades-Rodriguez M, Timmis A, Stogiannis D, et al. Socioeconomic deprivation and the incidence of 12 cardiovascular diseases in 1.9 million women and men: implications for risk prediction and prevention. PLoS ONE 2014;9:e104671.
15. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899-911.
16. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105-13.
17. George J, Rapsomaniki E, Pujades-Rodriguez M, et al. How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1, 937, 360 people. Circulation 2015;132:1320-8.
18. Walley T, Mantgani A. The UK general practice research database. Lancet 1997;350:1097-9.
19. Herrett E, Smeeth L, Walker L, et al. The Myocardial Ischaemia National Audit Project (MINAP). Heart 2010;96:1264-7.
20. Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 2013;346:f2350.
21. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995;34:261-4.
22. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
23. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
24. Ray JG, Mamdani MM, Geerts WH. Giant cell arteritis and cardiovascular disease in older adults. Heart 2005;91:324-8.
25. Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007;57:279-86.